Aevi Genomic Medicine LLC

Aevi Genomic Medicine — Medgenics — Q4 2014 Earnings Presentation

18 slides from Aevi Genomic Medicine's earnings presentation, Feb 13, 2015

  1. Slide 1: Q4 2014 Results

    Q4 2014 Results February 13, 2015

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results

  3. Slide 3: Agenda

    Agenda 3 • 2014 Recap • MDGN - 201 Clinical Update • Early Stage Pipeline • Collaborations • Q4 Financial Update • 2015 Milestones

  4. Slide 4: Significant Achievements of 2014

    Significant Achievements of 2014 4 • Re - engineered the TARGT ex vivo gene therapy platform – Created significant performance improvements in protein expression and duration of secretion • Demonstrated platform improvements in the open - label, ascending d ose study in ESRD patients – Demonstrated

  5. Slide 5: MDGN-201 Study Update

    MDGN-201 Study Update 5 medgenics

  6. Slide 6: MDGN-201 (TARGT EPO) Open Label Ascending Dose

    6 Trial MDGN - 201 TARGT EPO Location Israel Phase I - II Indication End Stage Renal Disease Sites Multi center Status Enrolling mid dose MDGN - 201 (TARGT EPO ) – Open Label Ascending Dose

  7. Slide 7: Patient Profile

    MDGN - 201 (TARGT EPO ) – Open Label Ascending Dose • End Stage Renal Disease (ESRD) – Renal failure and low baseline eEPO secretion – Require rHuEPO 2 - 3x/week • Hemodialysis dependent (3x weekly) – Significantly shortens red blood cell (RBC) lifespan – Ongoing blood loss from dialysis and testing

  8. Slide 8: MDGN-201 Phase 1/2 Trial Design

    MDGN - 201 (TARGT EPO ) – Open Label Ascending Dose 8 Clinical endpoints: (1) Serum eEPO levels (2) Hb levels (3) Duration (4) Safety Study Summary Group Treatment N A Low dose eEPO 18 - 25 IU/kg/day 3 + 3 * B Mid dose eEPO 35 - 45 IU/kg/day 3 + 3 * C High dose eEPO 55 - 65 IU/kg/day 3 + 3 * MDGN -

  9. Slide 9: Summary Patient Status – Low Dose Cohort

    9 Subject # Age Gender Dialysis (years) Medical History rHuEPO Run - in Dose (IU/ wk ) # of TARGT s Months Post Implant Status E101 70 M 4 hypertension, diabetes 12,000 3 8 Ongoing ; s table Hb E202 76 M 9 hypertension, stroke, MI 20,000 2 4 Ongoing; stable Hb E203 67 M 1 diabetes 20,000 3 3 Ongoing

  10. Slide 10: Progress To Date

    Progress To Date • Low - dose cohort fully enrolled – P ositive response to therapy at ~ 100x lower c max and 10x lower overall exposure vs rHuEPO – Low - dose well tolerated; no treatment related SAE’s – Inter - patient variability similar to that observed with other gene therapies • Demonstrated a

  11. Slide 11: The Need for Alternatives to Current EPO Therapies

    The Need for Alternatives to Current EPO Therapies 11 • Significant safety concerns related to rHuEPO remain – Increased risk of thromboembolic events (evidenced by CHOIR, TREAT studies) – Increased risk of cancer progression – Supra - therapeutic levels of rHuEPO have been implicated • FDA class la

  12. Slide 12: Opportunity for TARGT EPO

    Opportunity for TARGT EPO 12 • M imics natural system – Well characterized biology – Continuous, autologous, physiologic EPO – Superior safety and efficacy profile • Alternative to rHuEPO for patients inadequately or not treated due to: – H igh risk for thromboembolic events – History of cancer – Hy

  13. Slide 13: Orphan Indications for TARGT EPO

    Orphan Indications for TARGT EPO 13 INDICATION PATIENT / PAYOR NEED CLINICAL RATIONALE ESTIMATED PREVALENCE PERITONEAL DIALYSIS (PD) PD provides 20% cost reduction vs hemodialysis Improved compliance will boost outcomes and reduce costs for PD patients 20,000 (US) 6 ANEMIC CKD TRANSPLANT CANDIDATES

  14. Slide 14: Early Stage Pipeline

    Early S tage P ipeline • GLP - 2 – Produced both native GLP - 2 and Gattex ® – SCID mouse experiments demonstrated ability to produce clinically relevant levels of GLP - 2 – Achieved proof of biological activity as measured by villus lengthening – Pre - IMPD meeting mid year to determine development

  15. Slide 15: Collaboration Partners

    Collaboration Partners 15 PARTNER SCOPE KEY DELIVERABLES Children’s Hospital of Philadelphia (CHOP) Exclusive license to use the rare and orphan disease samples at the Center for Applied Genomics (CAG) for the purpose of developing and commercializing therapeutic treatments and diagnostic targets fo

  16. Slide 16: Financial Update

    Financial Update 6 medgenics

  17. Slide 17: Q4 2014 Results of Operations

    Q4 2014 - Results of Operations • Net R&D expenses for the 4 th Quarter were $3.8MM increasing from $2.1MM for the same period in 2013 due to an increase in license fees and research expenses • G&A expenses for the 4 th Quarter were $2.4MM decreasing from $3.8MM for the same period in 2013 mainly du

  18. Slide 18: 2015 Milestones

    2015 Milestones 18 PROGRAM TIMING RENAL ANEMIA Complete enrollment in low dose MDGN - 201 cohort ✓ Initiate enrollment in mid dose MDGN - 201 cohort ✓ Initiate Phase 2 study in Peritoneal Dialysis (PD), including: Q1 15 - Renal Anemia Transplant patients - ESA Hypo - responsive patients HEMATOLOGICA

Medgenics — Q4 2014 Earnings Presentation on 6ix